The US Food and Drug Administration (FDA) has approved the first generic of Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use eye drops to increase tear production in dry eye patients.

Viatris subsidiary Mylan Pharmaceuticals will manufacture the generic. Viatris president Rajiv Malik said the company had worked for nearly a decade not only to develop a more affordable product but also to remove all barriers to entry and achieve patient access.